Neurotoxicity From Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: NSABP C-07
Top Cited Papers
- 1 June 2007
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (16) , 2205-2211
- https://doi.org/10.1200/jco.2006.08.6652
Abstract
Purpose: The randomized, multicenter, phase III protocol C-07 compared the efficacy of adjuvant bolus fluorouracil and leucovorin (FULV) versus FULV with oxaliplatin (FLOX) in stage II or III colon cancer. Definitive analysis revealed an increase in 4-year disease-free survival from 67.0% to 73.2% in favor of FLOX. This study compares neurotoxicity between the treatments. Patients and Methods: Neurotoxicity was recorded for all patients using standard adverse event reporting. Patients at select institutions completed a neurotoxicity questionnaire through 18 months of follow-up. Results: A total of 2,492 patients enrolled onto C-07 and 400 patients enrolled onto the patient-reported substudy. Mean patient-reported neurotoxicity was higher with oxaliplatin throughout the 18 months of study (P < .0001). During therapy, patients receiving oxaliplatin experienced significantly more hand/foot toxicity (eg, “quite a bit” of cold-induced hand/foot pain 26% FLOX v 2.6% FULV) and overall weakness (eg, moderate weakness in 27.4% FLOX v 16.2% FULV). At 18 months, hand neuropathy had diminished, but patients who received oxaliplatin experienced continued foot discomfort (eg, moderate foot numbness and tingling for 22.1% FLOX v 4.6% FULV). Observer-reported neurotoxicity was low grade and primarily neurosensory rather than neuromotor. Sixty-eight percent in the FLOX group v 8% in the FULV group had neurotoxicity at their first on-treatment assessment. Time to resolution was significantly longer for those receiving oxaliplatin, and continued beyond 2 years for more than 10% in the oxaliplatin group. Conclusion: Oxaliplatin causes significant neurotoxicity. It is experienced primarily in the hands during therapy and in the feet during follow-up. In a minority of patients the neurotoxicity is long lasting.Keywords
This publication has 19 references indexed in Scilit:
- Peripheral neuropathy exacerbation associated with topical 5-fluorouracilAnti-Cancer Drugs, 2006
- Randomized Controlled Trial of Reduced-Dose Bolus Fluorouracil Plus Leucovorin and Irinotecan or Infused Fluorouracil Plus Leucovorin and Oxaliplatin in Patients With Previously Untreated Metastatic Colorectal Cancer: A North American Intergroup TrialJournal of Clinical Oncology, 2006
- The relationship between observer-based toxicity scoring and patient assessed symptom severity after treatment for head and neck cancer. A correlative cross sectional study of the DAHANCA toxicity scoring system and the EORTC quality of life questionnairesRadiotherapy and Oncology, 2006
- The Prevalence, Predictors, and Consequences of Peripheral Sensory Neuropathy in Older PatientsThe Journal of the American Board of Family Medicine, 2004
- Health-Related Quality of Life in Axillary Node-Negative, Estrogen Receptor-Negative Breast Cancer Patients Undergoing AC Versus CMF Chemotherapy: Findings from the National Surgical Adjuvant Breast and Bowel Project B-23Breast Cancer Research and Treatment, 2004
- Neurotoxicity of taxanes: Symptoms and quality of life assessmentBreast Cancer, 2004
- Measuring the side effects of taxane therapy in oncologyCancer, 2003
- Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracilAnti-Cancer Drugs, 2001
- A Rare Event of 5-Fluorouracil-Associated Peripheral NeuropathyAmerican Journal of Clinical Oncology, 1998
- Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric studyAnnals of Oncology, 1998